Onlyric 40 Tablet contains Febuxostat 40 mg, a xanthine oxidase inhibitor used primarily for the management of hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout attacks and promotes the dissolution of urate crystals deposited in joints and tissues. Onlyric 40 is indicated for long-term treatment of chronic hyperuricemia where urate deposition has already occurred, especially in patients who are intolerant to or inadequately managed by allopurinol. The tablet should be administered orally, with or without food, as directed by a healthcare professional. Dose adjustments may be necessary based on renal function and patient response. Common adverse effects include liver function abnormalities, nausea, and rash, and patients should be monitored regularly for liver enzyme levels during therapy. Onlyric 40 is contraindicated in patients with hypersensitivity to Febuxostat or in combination with azathioprine or mercaptopurine. It is essential to maintain adequate hydration to prevent renal complications. Consultation with a healthcare provider is recommended before initiating therapy.